

Jeremy Shefner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11950277/publications.pdf>

Version: 2024-02-01

29
papers

3,348
citations

331538

21
h-index

501076

28
g-index

29
all docs

29
docs citations

29
times ranked

4020
citing authors

#	ARTICLE	IF	CITATIONS
1	Electrodiagnostic criteria for diagnosis of ALS. <i>Clinical Neurophysiology</i> , 2008, 119, 497-503.	0.7	927
2	A revision of the El Escorial criteria - 2015. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 291-292.	1.1	373
3	A collagen-based nerve guide conduit for peripheral nerve repair: An electrophysiological study of nerve regeneration in rodents and nonhuman primates. <i>Journal of Comparative Neurology</i> , 1991, 306, 685-696.	0.9	342
4	Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. <i>Annals of Neurology</i> , 2009, 66, 235-244.	2.8	211
5	Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2010, 9, 481-488.	4.9	177
6	The effects of dexamipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. <i>Nature Medicine</i> , 2011, 17, 1652-1656.	15.2	166
7	Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 19-32.	1.1	135
8	Quantifying disease progression in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2014, 76, 643-657.	2.8	133
9	A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 266-271.	2.3	114
10	The Effects of Delayed Diagnosis and Treatment in Patients with an Occult Spinal Dysraphism. <i>Journal of Urology</i> , 1995, 154, 754-758.	0.2	94
11	Bladder Functional Changes Resulting from Lipomyelomeningocele Repair. <i>Journal of Urology</i> , 1992, 148, 592-594.	0.2	90
12	Clinical significance in the change of decline in ALSFRS-R. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 178-180.	2.3	82
13	Toward more efficient clinical trials for amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 259-265.	2.3	77
14	The El Escorial criteria: Strengths and weaknesses. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 1-7.	1.1	69
15	Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI18619). <i>Muscle and Nerve</i> , 2020, 61, 218-221.	1.0	51
16	Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e97803.	1.1	45
17	Respiratory measures in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 321-330.	1.1	44
18	Late Effects of Early Surgery on Lipoma and Lipomeningocele in Children Less Than 1 Year Old. <i>Journal of Urology</i> , 1997, 157, 1434-1437.	0.2	42

#	ARTICLE	IF	CITATIONS
19	Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 430-438.	2.3	33
20	Repeatability of Commonly Used Speech and Language Features for Clinical Applications. <i>Digital Biomarkers</i> , 2020, 4, 109-122.	2.2	29
21	Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. <i>International Journal of Cancer</i> , 1994, 57, 57-59.	2.3	24
22	The Awaji criteria for diagnosis of ALS. <i>Muscle and Nerve</i> , 2011, 44, 456-456.	1.0	22
23	ALS Untangled No. 20: The Deanna Protocol. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 319-323.	1.1	19
24	Electrodiagnosis of Motor Neuron Disease. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2013, 24, 139-151.	0.7	17
25	Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 266-276.	0.9	17
26	Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 15-23.	1.1	12
27	Would riluzole be efficacious in the new ALS trial design? "Authors' reply. <i>Lancet Neurology</i> , The, 2010, 9, 950-951.	4.9	1
28	Clinical significance in the change of decline in ALSFRS-R. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 0, , 1-3.	2.3	1
29	Automated semantic relevance as an indicator of cognitive decline: Out-of-sample validation on a large-scale longitudinal dataset. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12294.	1.2	1